tremelimumab-actl

tremelimumab-actl (IMJUDO) is an FDA-listed pharmaceutical active ingredient. Route of administration: intravenous. Current US regulatory status: approved.

IMJUDO is a marketed brand name for tremelimumab-actl. Check FDA Drugs@FDA for the current US label holder and prescribing information.

tremelimumab-actl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.